ReviewInternational journal of molecular medicine2026
Multi‑omics integration in osteoarthritis: Unraveling cell‑type‑specific gene‑metabolite networks for precision medicine (Review).
Review in International journal of molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Osteoarthritis (OA) is a heterogeneous joint disorder lacking disease‑modifying therapies. Recent advances in single‑cell transcriptomics, metabolomics, lipidomics, and spatial omics have enabled the reconstruction of cell‑type‑specific gene‑metabolite networks and revealed that metabolic reprogramming differs markedly across chondrocyte subsets, synovial fibroblasts and immune cells. Lipid metabolism disturbances, particularly those involving glycerophospholipids, sphingolipids and cholesterol, are consistently linked to OA severity and pain generation. Integrative multi‑omics approaches further facilitate molecular endotyping, informing patient stratification and endotype‑driven clinical trial design. However, a systematic synthesis of these emerging findings is still lacking. This review critically synthesizes current multi‑omics integration strategies, delineates cell‑type‑specific metabolic networks derived from transcriptomic and metabolomic data and discusses their implications for precision medicine in OA, while also considering the emerging contributions of spatial omics technologies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.